Novartis' Sandoz: Between Generics and Pharma

Sandoz, which made a significant investment in bio-similars as a way to differentiate itself from its generic drug industry peers, has to negotiate with its parent company and the innovative pharma division on how best to commercialize its bio-similar portfolio. What is the best way to balance the parenting advantage of Novartis with the unique demands of the generic drug industry?
Collection: HBSP (USA)
Ref: HBS-114033-E
Format: PDF
Number of pages: 24
Publication Date: Mar 10, 2014
Language: English

Description

Sandoz, which made a significant investment in bio-similars as a way to differentiate itself from its generic drug industry peers, has to negotiate with its parent company and the innovative pharma division on how best to commercialize its bio-similar portfolio. What is the best way to balance the parenting advantage of Novartis with the unique demands of the generic drug industry?
Read more
Year: 2014
Industry Setting: Pharmaceuticals

Novartis' Sandoz: Between Generics and Pharma

Options of use
Number of copies
- +
As low as €8.53

Are you interested in this product?

Add it to your favourites so that your institution can purchase it.
You'll be able to order once your profile has been validated.
Add to wishlist

Leave your rating

"Novartis' Sandoz: Between Generics and Pharma"